Molecular 'Breadcrumb Trail' Helps Melanoma Spread

Scientists have discovered that melanoma cells are drawn to follow the 'trail' of a naturally-occurring molecule in the body, which directs this serious type of skin cancer to spread.

This is according to research published in PLOS Biology. The team at the Cancer Research UK Beatson Institute at the University of Glasgow, revealed that melanoma cells give themselves the 'green light' to move using the molecule - a type of fatty chemical called lysophosphatidic acid (LPA). This signal prompts them to travel and spread in the body.

Fashion Trends Linked With Increased Melanoma Cases: Study
Fashion trends and socioeconomic factors played a major role in the rise of melanoma cases over the past century, reveals a new study.

The researchers showed in cancer cell lines and mice that tumour cells start their journey by first breaking down a nearby source of LPA molecules. Once nearby levels of LPA are depleted, the cells then move out of the tumour in search of more. This creates a trail leading to the bloodstream and onto a new site in the body.

Unlike other cancers, where cells stick tightly to their neighbours, the structure of melanoma cells means they are primed to spread from the start. So as soon as they have taken the directions given by LPA they start moving. This means the cancer can be difficult to treat because it spreads quickly and aggressively.

The researchers filmed the cells and found that they move at speed, spreading around the body at a pace of a millimetre per day. This speed means a cell can arrive anywhere in the body within a few weeks.

Monoclonal Antibody Nivolumab Shows Signs of Superior Response Rate in Advanced Melanoma
In patients whose melanoma has progressed after treatment with ipilimumab, the monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1].

Lead author, Professor Robert Insall, Cancer Research UK scientist at the Beatson Institute at the University of Glasgow, said: "Our exciting findings show that skin cancer cells create their own 'green light' signal to start spreading, and are lured to travel around the body by a trail of these fatty molecules".

"The next step will be to find how the melanoma cells break down the LPA molecules to see if this sparks ideas for new ways to stop the cancer from spreading. At the moment our research is still in early stages but we hope this could help doctors to make sure this cancer doesn't spread."

New Data on Combination Therapies for Melanoma
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma.

The rates of people diagnosed with melanoma are five times higher than 40 years ago. Over 13,000 people are diagnosed with melanoma every year in the UK. Each year, around 2,200 people die from the disease.

Professor Nic Jones, Cancer Research UK's chief scientist, said: "Sadly there are few options available for patients whose melanoma has spread, which is especially concerning as this type of cancer has risen rapidly since the 70s".

Life Extended in Advance Melanoma Patients With Targeted Combination Therapy
Major declines in the risk of disease progression and death in people with metastatic melanoma was reported as the effect of a targeted combination drug therapy.

"Research like this is crucial to find effective ways to limit the spread of tumours and increase the chances for more successful treatment of this horrible disease.

"We can all also reduce our risk of the disease by keeping safe in the sun. When the sun is strong it's best to cover up with clothes and spend time in the shade to protect your skin from sunburn and reduce your risk of skin cancer."

Source-Eurekalert